美国 · 股市与财经 · MarketWatch
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
Martin Shkreli, a former hedge-fund manager known as “Pharma Bro,” is back in the crosshairs of U.S. regulators for influencing biopharma stocks even though he is banned from…
在 MarketWatch 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketwatch.com)
